查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929280

肽類化合物市場按類型、合成方法、應用和最終用戶分類，全球預測（2026-2032年）

Peptoids Market by Type, Synthesis Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年肽類化合物市場價值為 7,088 萬美元，預計到 2026 年將成長至 7,816 萬美元，年複合成長率為 10.81%，到 2032 年將達到 1.4545 億美元。

關鍵市場統計數據
基準年 2025 7088萬美元
預計年份：2026年 7816萬美元
預測年份 2032 1.4545億美元
複合年成長率 (%) 10.81%

本書對胜肽類化合物的基本原理進行了清晰而引人入勝的概述，重點介紹了它們的結構優勢、技術基礎以及在研發領域的潛在應用。

胜肽類化合物是一類胜肽模擬物，其特徵在於胜肽骨架的氮原子上連接有側鏈。這種結構賦予它們蛋白酶穩定性、結構多樣性和可調控的物理性質。這些合成寡聚物彌合了小分子和生物製藥之間的鴻溝，為分子識別、表面功能化和可工程化的生物活性提供了傳統胜肽難以實現的獨特可能性。它們的模組化特性使其能夠進行高通量設計和組合化學方法的研究，使其成為探索性研究和應用研究的理想選擇。

合成技術的進步、運算設計和混合平台策略如何重塑胜肽類化合物的開發和應用途徑

由於合成調查方法、數位化設計以及這些寡聚物的跨學科應用的創新，胜肽類化合物領域正在經歷變革性變化。固相和液相技術的進步縮短了反應週期，提高了序列保真度，並實現了更長、更複雜胜肽類化合物結構的可靠合成。同時，微波輔助液相合成方法與先進的保護基策略的結合，拓展了化學家可用的實用方法，並降低了複雜功能化和規模化生產的門檻。

評估近期關稅政策變化如何影響胜肽類藥物開發生態系統的供應鏈、採購選擇和營運韌性

美國2025年實施的關稅和貿易政策措施，為胜肽類化合物的供應鏈、籌資策略和合作夥伴選擇帶來了新的變化。關稅導致的成本結構變化迫使各組織重新評估籌資策略，許多團隊正在考慮供應商網路多元化，以降低依賴單一供應商的風險。隨著採購營運日益複雜，品質保證和供應商選擇流程變得愈發重要，這影響著採購和研發部門如何分配時間和預算用於供應商審核和緊急時應對計畫。

策略性細分分析加速開發決策：洞察胜肽類骨架選擇、應用需求、最終使用者能力與合成路線之間的關係

細分分析揭示了類型、應用、最終用戶和合成方法等各個維度上的獨特機會和挑戰，從而指導策略指南。環狀胜肽和線性胜肽之間的差異驅動著功能設計考量：環狀結構提供更優的結構約束，有利於高親和性標靶結合；而線性序列則便於文庫擴充和模組化功能化，從而適用於篩檢宣傳活動。了解這些互補作用有助於企業選擇適合特定生物學假設和材料功能的支架。

影響胜肽類化合物研究、生產和合作的區域趨勢和戰略優勢（美洲、歐洲、中東和非洲、亞太地區）

區域趨勢影響研究重點、法規結構和供應鏈結構對胜肽類化合物應用和商業化的影響。在美洲，學術研究機構和轉化生物技術中心的集中佈局有利於快速原型製作和早期檢驗。對生命科學基礎設施的大力投資以及臨床網路的暢通，促進了夥伴關係的建立，從而加速了從臨床前階段到臨床階段的過渡。同時，國內生產能力和政策環境也影響關鍵試劑和特殊聚合物回流（本土化）的決策。

透過合成自動化、整合服務和有針對性的夥伴關係，為企業創造競爭優勢，從而支援其胜肽類化合物開發平臺。

肽類化合物生態系統中的領導者憑藉先進的合成技術、平台整合以及連接學術界和產業界的夥伴關係脫穎而出。投資於自動化合成平台和可擴展製程技術的公司能夠獲得高通量優勢，從而支持藥物發現和早期開發。將這種營運能力與高解析度質譜和正交生物物理分析等強大的分析框架相結合的公司，可以加快候選藥物的篩選速度並降低後續研發的失敗率。

為領導者建構合成柔軟性、供應鏈韌性、跨職能設計整合以及加速轉化的夥伴關係模式提供實用建議

產業領導者應優先投資於能夠增強胜肽類化合物相關計劃的韌性、速度和實用化契合度的投資。首先，建構可在固相和液相工作流程之間靈活切換的合成能力，能夠幫助團隊最佳化序列複雜性、通量和規模。將資源投入到模組化自動化和檢驗的製程控制中，將縮短實驗啟動時間並提高可重複性，這對於下游監管互動和合作夥伴協作至關重要。

本研究採用的調查方法為透明、嚴謹的混合方法研究途徑，結合專家訪談、技術文獻綜述、專利分析和供應鏈映射來檢驗研究結果。

本分析的調查方法結合了定性和定量方法，以確保獲得全面且基於證據的見解。主要研究包括對來自學術實驗室、生物技術創新者、受託研究機構和監管諮詢公司的領域專家進行結構化訪談，以收集關於合成方法、應用檢驗和採購行為的第一手資料。與這些專家的對話旨在了解不同終端使用者類型的實際操作情況、技術瓶頸和新興機會。

整合了胜肽類創新的戰略意義以及將科學潛力轉化為應用成果所需的操作選擇

肽類化合物憑藉其許多實用優勢，在研究、診斷和治療技術領域佔據著極具吸引力的地位，並擁有廣泛的應用前景。它們兼具合成模組化、結構穩健性和易於計算設計等特點，使研究機構能夠以前所未有的效率應對複雜的生物標的和功能材料的挑戰。隨著合成和分析技術的不斷成熟，胜肽類化合物有望成為現有方法的強大補充，並開闢新的創新途徑。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 胜肽類物質市場（按類型分類）

  • 圓
  • 線性類型

9. 依合成方法分類的胜肽化合物市場

  • 固相合成
    • 博克化學
    • 氟化物化學
  • 溶液相合成
    • 傳統暖氣
    • 微波輔助

第10章 按應用分類的胜肽市場

  • 生物醫學研究
    • 生物鑑定
    • 作用機轉研究
  • 診斷
    • 生物標記檢測
    • 影像劑
  • 藥物輸送
    • 控釋
      • 水凝膠載體
      • 聚合物載體
    • 精準投放
  • 藥物發現
    • 高通量篩檢
    • 分子建模
  • 組織工程
    • 細胞黏附
    • 支架功能化

第11章 以最終用戶分類的胜肽類市場

  • 學術和研究機構
    • 政府研究機構
    • 大學
  • 生技公司
    • 診斷試劑
    • 治療藥物
  • CRO
    • 臨床
    • 臨床前
  • 製藥公司
    • 大型製藥企業
    • 學名藥生產商

第12章 胜肽類物質市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 胜肽類物質市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國胜肽類藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國胜肽類市場

第16章：中國的胜肽類市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abcam plc
  • AnaSpec, Inc.
  • Apeptide Co., Ltd.
  • Bachem Holding AG
  • Biomatik Corporation
  • Bio-Synthesis, Inc.
  • ChemPep Inc.
  • ChinaPeptides Co., Ltd.
  • CPC Scientific Inc.
  • Creative Peptides LLC
  • GenScript Biotech Corporation
  • GenScript USA Inc.
  • GL Biochem Ltd.
  • JPT Peptide Technologies GmbH
  • Lonza Group AG
  • NovoPro Bioscience Co., Ltd.
  • Pepscan Presto BV
  • Peptide 2.0 Inc.
  • Peptides International LLC
  • Peptones
  • Sigma-Aldrich Co. LLC
  • SynPeptide Co., Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0A3806951749

The Peptoids Market was valued at USD 70.88 million in 2025 and is projected to grow to USD 78.16 million in 2026, with a CAGR of 10.81%, reaching USD 145.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 70.88 million
Estimated Year [2026] USD 78.16 million
Forecast Year [2032] USD 145.45 million
CAGR (%) 10.81%

A clear and compelling overview of peptoid fundamentals that outlines structural advantages, technological enablers, and translational potential for research and development

Peptoids are a distinctive class of peptidomimetics characterized by side chains attached to the nitrogen atom of the peptide backbone rather than the alpha carbon, endowing them with proteolytic stability, structural versatility, and tunable physicochemical properties. These synthetic oligomers bridge the gap between small molecules and biologics, offering unique opportunities for molecular recognition, surface functionalization, and designable bioactivity that conventional peptides sometimes cannot achieve. Their modularity supports high-throughput design and combinatorial chemistry approaches, making them attractive for exploratory research and translational applications.

Recent advances in automated synthesis platforms and cheminformatics have accelerated the discovery and optimization of peptoid sequences with targeted binding and functional profiles. As researchers increasingly prioritize stability, manufacturability, and adaptability, peptoids have emerged as viable alternatives in contexts where protease resistance and membrane permeability are critical. Additionally, the expanding toolkit for characterization, including enhanced mass spectrometry methods and structural modeling, has improved confidence in sequence-activity relationships, enabling more deliberate progression from bench-scale discovery to applied development.

The intellectual landscape around peptoids also reflects interdisciplinary collaboration, drawing expertise from synthetic chemistry, molecular biology, materials science, and computational design. This convergence is creating new paradigms for therapeutic leads, diagnostics probes, and biomaterials. With those developments, stakeholders are reassessing traditional pipelines to integrate peptoid-enabled modalities that can offer differentiated performance and potentially streamline translational hurdles that affect conventional peptide-based programs.

How advances in synthesis, computational design, and hybrid platform strategies are reshaping peptoid development and translational pathways

The peptoid landscape is undergoing transformative shifts driven by innovations in synthetic methodology, digital design, and cross-disciplinary application of these oligomers. Advances in solid-phase and solution-phase techniques have reduced cycle times and improved sequence fidelity, enabling longer and more complex peptoid constructs to be synthesized reliably. Concurrently, integration of microwave-assisted solution-phase methods and refined protecting group strategies has expanded the practical repertoire available to chemists, reducing barriers to complex functionalization and scale-up.

Computational design tools and machine learning models have enhanced the ability to predict structure-activity relationships, accelerating lead identification and screening throughput. This digital augmentation has enabled rational selection of monomer libraries and facilitated iterative optimization cycles that are faster and less resource intensive than traditional empirical approaches. The resulting acceleration in candidate triage improves the efficiency of downstream validation and allows multidisciplinary teams to focus on higher-probability leads.

There is also a notable shift toward hybrid approaches that combine peptoids with other chemical or biological scaffolds to create multifunctional platforms for targeted delivery, imaging, and tissue engineering. Sustainability considerations and green chemistry principles are influencing reagent selection and solvent usage, prompting innovations in waste-minimizing synthesis workflows. Collectively, these shifts are redefining how peptoids are conceived, developed, and positioned within therapeutic, diagnostic, and material science portfolios.

Assessing how recent tariff policy shifts are altering supply chains, sourcing choices, and operational resilience across peptoid development ecosystems

The imposition of tariffs and trade policy measures in the United States in 2025 has introduced new dynamics across peptoid supply chains, procurement strategies, and partner selection. Tariff-induced cost structures have compelled organizations to reevaluate sourcing strategies for monomers, resins, and specialized reagents, with many teams considering diversified supplier networks to mitigate single-source exposure. As procurement complexity increases, quality assurance and supplier qualification processes have become more prominent, shaping how procurement and R&D teams allocate time and budget toward supplier audits and contingency planning.

Tariffs have also affected collaboration models, prompting tighter integration between domestic academic labs and industry partners to localize critical steps such as oligomer assembly or late-stage functionalization. Regulatory compliance and customs paperwork have added administrative layers that lengthen lead times and require more rigorous inventory planning. In parallel, some organizations have accelerated investment in internal synthesis capabilities or contracted with local contract research and manufacturing organizations to reduce dependency on cross-border shipments and to preserve project timelines.

Strategically, tariffs have encouraged a reexamination of value chains where high-value-added activities, such as complex sequence design and analytics, remain domestically concentrated while commodity inputs are sourced globally. Firms that adapt to this environment by optimizing just-in-time workflows, strengthening supplier diversification, and investing in modular synthesis infrastructure position themselves to maintain continuity of research operations and protect translational timelines under evolving trade conditions.

Strategic segmentation insights that align peptoid scaffold choice, application needs, end-user capabilities, and synthesis pathways to accelerate development decisions

Segmentation analysis reveals distinct opportunities and barriers across type, application, end-user, and synthesis method dimensions that guide strategic prioritization. Type distinctions between cyclic and linear peptoids drive functional design considerations; cyclic constructs often offer enhanced conformational constraint advantageous for high-affinity target engagement while linear sequences enable facile library expansion and modular functionalization for screening campaigns. Understanding these complementary roles helps organizations select the right scaffold for a given biological hypothesis or material function.

Application-driven segmentation spans biomedical research, diagnostics, drug delivery, drug discovery, and tissue engineering, each with unique technical expectations and validation pathways. Biomedical research initiatives leverage peptoids for biological assays and mechanistic studies where stability and tunability reduce experimental variability. Diagnostics applications target biomarker detection and imaging agents that capitalize on sequence-specific binding and chemical robustness. Drug delivery efforts emphasize controlled release and targeted delivery strategies, with controlled release further differentiated by hydrogel-based carriers and polymer-based carriers that offer distinct release kinetics and formulation considerations. Drug discovery programs apply high-throughput screening and molecular modeling to accelerate hit identification while tissue engineering work focuses on cell adhesion and scaffold functionalization to improve integration and biocompatibility.

End-user segmentation highlights the varied procurement behaviors and technical capabilities of academic and research institutes, biotechnology companies, contract research organizations, and pharmaceutical companies. Within academic settings, government laboratories and universities prioritize exploratory science and tool development, whereas biotechnology companies differentiate between diagnostics and therapeutics teams that emphasize either speed to validation or clinical translation. Contract research organizations operate across clinical and preclinical services, offering scalability and regulatory know-how. Pharmaceutical organizations range from large integrated developers to generic manufacturers, each with distinct risk tolerances and investment horizons. Synthesis method segmentation clarifies the trade-offs between solid-phase synthesis, with Boc and Fmoc chemistries offering well-established workflows for resin-based assembly, and solution-phase synthesis, where conventional heating and microwave-assisted approaches can enable batch flexibility and process intensification depending on throughput and scale requirements.

Synthesizing insights across these segmentation axes enables stakeholders to align technical development with user expectations. For example, a therapeutic program prioritizing target engagement and serum stability might prefer cyclic peptoids synthesized via solid-phase Fmoc workflows and validated through high-throughput screening, while a diagnostics initiative focused on imaging could select linear constructs optimized through molecular modeling and produced using microwave-assisted solution-phase methods to accelerate iterative prototyping. These alignment strategies reduce translational friction and inform investment priorities across R&D and manufacturing operations.

Regional dynamics and strategic advantages across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence peptoid research, manufacturing, and collaboration

Regional dynamics shape how research priorities, regulatory frameworks, and supply chain configurations influence peptoid adoption and commercialization. In the Americas, a concentration of academic research institutions and translational biotech hubs supports rapid prototyping and early-stage validation. Robust investment in life sciences infrastructure and access to clinical networks facilitate partnerships that can accelerate preclinical-to-clinical progression. At the same time, domestic manufacturing capabilities and policy environments influence onshoring decisions for critical reagents and specialized polymers.

In Europe, Middle East & Africa, regulatory harmonization efforts and strong materials science expertise create fertile ground for collaborative consortia that bridge academic insight and industrial scale-up. Public-private partnerships in this region often emphasize sustainability and compliance, encouraging adoption of greener synthesis workflows and rigorous quality management systems. Regional funding programs and cross-border research networks support translational projects that combine diagnostic innovation with biomaterials applications.

Across Asia-Pacific, rapid expansion of biotechnology ecosystems, enhanced manufacturing capacity, and strong contract research service providers enable accelerated scaling of synthesis and characterization activities. The region's emphasis on cost-effective production and process optimization makes it a strategic node for reagent sourcing and manufacturing partnerships. Simultaneously, rising clinical trial activity and collaborative research initiatives with global partners position the region as a major contributor to both discovery and development efforts. Understanding these regional nuances allows organizations to design engagement strategies that leverage local strengths while mitigating logistical and regulatory risks.

How companies are creating competitive advantage through synthesis automation, integrated services, and targeted partnerships to support peptoid development pipelines

Leading organizations in the peptoid ecosystem are differentiating through capabilities in advanced synthesis, platform integration, and partnerships that bridge academia and industry. Companies investing in automated synthesis platforms and scalable process technologies gain a throughput advantage that supports both discovery and early development efforts. Firms that combine this operational capability with strong analytical frameworks-such as high-resolution mass spectrometry and orthogonal biophysical assays-can accelerate candidate qualification and reduce downstream attrition.

Strategic alliances with academic groups and technology licensors are common, enabling rapid access to novel monomer chemistries and functionalization strategies. Contract research and manufacturing organizations have positioned themselves as critical enablers by offering modular services that span prototyping to regulatory-compliant production. Organizations that provide integrated service models, including sequence design, ADME/Tox screening, and formulation support, are increasingly valued by customers seeking end-to-end solutions.

Competitive advantage also arises from focused specialization, where companies concentrate on niche applications such as imaging probes, controlled-release platforms, or scaffold functionalization for tissue engineering. These specialist teams develop deep domain knowledge and proprietary workflows that enhance value for customers with specific technical requirements. Collectively, these company-level strategies underscore the importance of combining technical excellence, strategic partnerships, and service integration to capture opportunities across the peptoid value chain.

Actionable recommendations for leaders to build synthesis flexibility, supply chain resilience, cross-functional design integration, and partnership models that accelerate translation

Industry leaders should prioritize investments that strengthen resilience, speed, and translational alignment across peptoid initiatives. First, building flexible synthesis capabilities that can shift between solid-phase and solution-phase workflows allows teams to optimize for sequence complexity, throughput, and scale. Allocating resources to modular automation and validated process controls reduces time-to-experiment and improves reproducibility, which is critical for downstream regulatory interactions and partner collaborations.

Second, organizations should formalize supplier diversification and inventory strategies to mitigate trade-related disruptions and ensure continuity of critical inputs. Establishing long-term agreements with multiple qualified suppliers, while maintaining in-house contingency capabilities for high-value synthesis steps, will reduce exposure to external shocks and preserve research timelines. Complementary to this, strengthening quality assurance and supplier qualification programs ensures that alternative sourcing does not compromise analytical or biological performance.

Third, fostering deeper collaboration between computational chemists, synthetic teams, and application scientists will yield design cycles that are both efficient and hypothesis-driven. Embedding iterative modeling and empirical validation reduces wasted cycles and enables more precise candidate advancement. Finally, companies should consider focused partnerships with contract research and manufacturing organizations to accelerate scale-up and regulatory preparation, while maintaining core capabilities in design and quality oversight to protect intellectual property and strategic control.

A transparent and rigorous mixed-methods research approach combining expert interviews, technical literature review, patent analysis, and supply chain mapping to validate insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to ensure comprehensive, evidence-based insights. Primary research included structured interviews with domain experts from academic laboratories, biotech innovators, contract research providers, and regulatory consultants, providing direct perspectives on synthesis practices, application validation, and procurement behaviors. These expert conversations were designed to capture operational realities, technological bottlenecks, and emergent opportunities across different end-user types.

Secondary research encompassed a systematic review of peer-reviewed literature, patent filings, conference proceedings, and regulatory guidance documents to contextualize scientific advances, intellectual property trends, and compliance frameworks. Technical protocols and analytical method papers were examined to assess reproducibility and scalability of synthesis routes, while clinical registries and preclinical study reports were consulted to track translational progress. Supply chain mapping exercises and procurement trend analyses provided additional visibility into sourcing dynamics and logistics.

To ensure rigor, findings were triangulated across data sources and validated through follow-up expert consultations. Scenario testing and sensitivity assessments were employed to explore how changes in trade policy, synthesis technology adoption, and regional investment patterns could affect strategic priorities. The methodology emphasized transparency in assumptions and careful delineation of technical versus commercial drivers to support actionable conclusions that stakeholders can apply to their R&D and operational planning.

Synthesizing the strategic implications of peptoid innovation and the operational choices required to translate scientific potential into applied outcomes

Peptoids occupy a compelling niche with practical advantages that support diverse applications across research, diagnostics, and therapeutic enabling technologies. The combination of synthetic modularity, structural resilience, and amenability to computational design equips organizations to address complex biological targets and functional materials challenges with renewed efficiency. As synthesis and analytical capabilities continue to mature, peptoids are poised to complement existing modalities and open new pathways for innovation.

Success will depend on the ability of stakeholders to align scaffold selection, synthesis method, and end-user needs while navigating evolving trade and regulatory landscapes. Organizations that invest in flexible synthesis infrastructure, robust supplier strategies, and cross-functional design workflows will be better positioned to translate peptoid potential into tangible research and product outcomes. Ultimately, strategic coordination between technical teams, procurement functions, and external partners will determine how quickly and effectively peptoids are integrated into mainstream R&D and applied solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptoids Market, by Type

  • 8.1. Cyclic
  • 8.2. Linear

9. Peptoids Market, by Synthesis Method

  • 9.1. Solid-Phase Synthesis
    • 9.1.1. Boc Chemistry
    • 9.1.2. Fmoc Chemistry
  • 9.2. Solution-Phase Synthesis
    • 9.2.1. Conventional Heating
    • 9.2.2. Microwave-Assisted

10. Peptoids Market, by Application

  • 10.1. Biomedical Research
    • 10.1.1. Biological Assays
    • 10.1.2. Mechanistic Studies
  • 10.2. Diagnostics
    • 10.2.1. Biomarker Detection
    • 10.2.2. Imaging Agents
  • 10.3. Drug Delivery
    • 10.3.1. Controlled Release
      • 10.3.1.1. Hydrogel-Based Carriers
      • 10.3.1.2. Polymer-Based Carriers
    • 10.3.2. Targeted Delivery
  • 10.4. Drug Discovery
    • 10.4.1. High-Throughput Screening
    • 10.4.2. Molecular Modeling
  • 10.5. Tissue Engineering
    • 10.5.1. Cell Adhesion
    • 10.5.2. Scaffold Functionalization

11. Peptoids Market, by End User

  • 11.1. Academic & Research Institutes
    • 11.1.1. Government Laboratories
    • 11.1.2. Universities
  • 11.2. Biotechnology Companies
    • 11.2.1. Diagnostics
    • 11.2.2. Therapeutics
  • 11.3. CROs
    • 11.3.1. Clinical
    • 11.3.2. Preclinical
  • 11.4. Pharmaceutical Companies
    • 11.4.1. Big Pharma
    • 11.4.2. Generic Pharma

12. Peptoids Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Peptoids Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peptoids Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Peptoids Market

16. China Peptoids Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abcam plc
  • 17.6. AnaSpec, Inc.
  • 17.7. Apeptide Co., Ltd.
  • 17.8. Bachem Holding AG
  • 17.9. Biomatik Corporation
  • 17.10. Bio-Synthesis, Inc.
  • 17.11. ChemPep Inc.
  • 17.12. ChinaPeptides Co., Ltd.
  • 17.13. CPC Scientific Inc.
  • 17.14. Creative Peptides LLC
  • 17.15. GenScript Biotech Corporation
  • 17.16. GenScript USA Inc.
  • 17.17. GL Biochem Ltd.
  • 17.18. JPT Peptide Technologies GmbH
  • 17.19. Lonza Group AG
  • 17.20. NovoPro Bioscience Co., Ltd.
  • 17.21. Pepscan Presto B.V.
  • 17.22. Peptide 2.0 Inc.
  • 17.23. Peptides International LLC
  • 17.24. Peptones
  • 17.25. Sigma-Aldrich Co. LLC
  • 17.26. SynPeptide Co., Ltd.
  • 17.27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTOIDS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTOIDS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTOIDS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTOIDS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTOIDS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTOIDS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTOIDS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTOIDS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PEPTOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PEPTOIDS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTOIDS MARKET SIZE, BY CYCLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTOIDS MARKET SIZE, BY CYCLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTOIDS MARKET SIZE, BY CYCLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTOIDS MARKET SIZE, BY LINEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTOIDS MARKET SIZE, BY LINEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTOIDS MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTOIDS MARKET SIZE, BY BOC CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTOIDS MARKET SIZE, BY BOC CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTOIDS MARKET SIZE, BY BOC CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTOIDS MARKET SIZE, BY FMOC CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTOIDS MARKET SIZE, BY FMOC CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTOIDS MARKET SIZE, BY FMOC CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTOIDS MARKET SIZE, BY CONVENTIONAL HEATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTOIDS MARKET SIZE, BY CONVENTIONAL HEATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTOIDS MARKET SIZE, BY CONVENTIONAL HEATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTOIDS MARKET SIZE, BY MICROWAVE-ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTOIDS MARKET SIZE, BY MICROWAVE-ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTOIDS MARKET SIZE, BY MICROWAVE-ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTOIDS MARKET SIZE, BY BIOLOGICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTOIDS MARKET SIZE, BY BIOLOGICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTOIDS MARKET SIZE, BY BIOLOGICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTOIDS MARKET SIZE, BY MECHANISTIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTOIDS MARKET SIZE, BY MECHANISTIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTOIDS MARKET SIZE, BY MECHANISTIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTOIDS MARKET SIZE, BY BIOMARKER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTOIDS MARKET SIZE, BY BIOMARKER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTOIDS MARKET SIZE, BY BIOMARKER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTOIDS MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTOIDS MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTOIDS MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTOIDS MARKET SIZE, BY HYDROGEL-BASED CARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTOIDS MARKET SIZE, BY HYDROGEL-BASED CARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTOIDS MARKET SIZE, BY HYDROGEL-BASED CARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTOIDS MARKET SIZE, BY POLYMER-BASED CARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTOIDS MARKET SIZE, BY POLYMER-BASED CARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTOIDS MARKET SIZE, BY POLYMER-BASED CARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTOIDS MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTOIDS MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTOIDS MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTOIDS MARKET SIZE, BY HIGH-THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTOIDS MARKET SIZE, BY HIGH-THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTOIDS MARKET SIZE, BY HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTOIDS MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTOIDS MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTOIDS MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTOIDS MARKET SIZE, BY CELL ADHESION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTOIDS MARKET SIZE, BY CELL ADHESION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEPTOIDS MARKET SIZE, BY CELL ADHESION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTOIDS MARKET SIZE, BY SCAFFOLD FUNCTIONALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTOIDS MARKET SIZE, BY SCAFFOLD FUNCTIONALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTOIDS MARKET SIZE, BY SCAFFOLD FUNCTIONALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTOIDS MARKET SIZE, BY GOVERNMENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEPTOIDS MARKET SIZE, BY GOVERNMENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTOIDS MARKET SIZE, BY GOVERNMENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEPTOIDS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTOIDS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PEPTOIDS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PEPTOIDS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTOIDS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEPTOIDS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTOIDS MARKET SIZE, BY CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEPTOIDS MARKET SIZE, BY CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTOIDS MARKET SIZE, BY CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTOIDS MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEPTOIDS MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTOIDS MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEPTOIDS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTOIDS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PEPTOIDS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTOIDS MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PEPTOIDS MARKET SIZE, BY BIG PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTOIDS MARKET SIZE, BY BIG PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PEPTOIDS MARKET SIZE, BY GENERIC PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTOIDS MARKET SIZE, BY GENERIC PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEPTOIDS MARKET SIZE, BY GENERIC PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PEPTOIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL PEPTOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 284. GCC PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. GCC PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. GCC PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 287. GCC PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. GCC PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 291. GCC PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 292. GCC PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 293. GCC PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 294. GCC PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 295. GCC PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 296. GCC PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. GCC PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 298. GCC PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 300. GCC PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 335. G7 PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 336. G7 PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. G7 PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 338. G7 PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 339. G7 PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 340. G7 PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 341. G7 PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 342. G7 PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 343. G7 PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 344. G7 PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 345. G7 PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 346. G7 PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 347. G7 PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 348. G7 PEPTOIDS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 349. G7 PEPTOIDS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 350. G7 PEPTOIDS MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 351. G7 PEPTOIDS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 352. NATO PEPTOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 353. NATO PEPTOIDS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. NATO PEPTOIDS MARKET SIZE, BY SYNTHESIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 355. NATO PEPTOIDS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 356. NATO PEPTOIDS MARKET SIZE, BY SOLUTION-PHASE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 357. NATO PEPTOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 358. NATO PEPTOIDS MARKET SIZE, BY BIOMEDICAL RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 359. NATO PEPTOIDS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 360. NATO PEPTOIDS MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 361. NATO PEPTOIDS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 362. NATO PEPTOIDS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 363. NATO PEPTOIDS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 364. NATO PEPTOIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 365. NATO PEP